Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 67 results for ulcerative colitis

  1. What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis?

    aminosalicylate for induction of remission for people with moderate ulcerative colitis? Any explanatory notes(if applicable) Source...

    Research recommendation
    Published
    25 October 2019

  2. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

    NICE guideline
    Published
    3 May 2019
    View recommendations

    Sections for NG129

  3. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

    Medtech innovation briefing
    Published
    12 July 2022

  4. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 March 2014

  5. What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

    and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?...

    Research recommendation
    Published
    25 October 2019

  6. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  8. Adenoma types and risk of colorectal cancer:- Does the risk of colorectal cancer depend on the type of adenoma?

    Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date...

    Research recommendation
    Published
    9 June 2015

  9. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 June 2018
    View quality statements

    Sections for QS170

  10. Natural history of progression to colorectal cancer in people at increased risk:- What is the natural history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas?

    Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date...

    Research recommendation
    Published
    9 June 2015

  11. Effectiveness of biomarkers for determining level of risk of colorectal cancer:- Which biomarkers, including epigenic and genetic markers, are predictors of colorectal cancer? How should these be used to improve risk stratification?

    Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date...

    Research recommendation
    Published
    9 June 2015

  12. Surveillance programmes for people at increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and cancer-related survival in people at increased risk of colorectal cancer?

    Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date...

    Research recommendation
    Published
    9 June 2015

  13. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS114

  14. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    17 January 2017

  15. In a mild-to-moderate first presentation or inflammatory exacerbation of proctitis that is resistant to standard treatment, what is the effectiveness of topical immunomodulators, such as tacrolimus, in achieving clinical remission and what is the most effective formulation (suppository/ointment)?

    immunomodulators. Source guidance details Comes from guidance Ulcerative colitis: management Number NG130 Date issued May 2019

    Research recommendation
    Published
    25 October 2019